Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?

Nat Biotechnol. 2018 Dec 6;36(12):1146-1149. doi: 10.1038/nbt.4308.

Authors

Mateo Aboy¹, Cristina Crespo¹, Kathleen Liddell¹, Johnathon Liddicoat¹, Matthew Jordan¹

Affiliation

¹ Centre for Law, Medicine, and Life Sciences, Faculty of Law, University of Cambridge, Cambridge, UK.

PMID: 30520866
DOI: 10.1038/nbt.4308

No abstract available

MeSH terms

Biological Products
Biotechnology / legislation & jurisprudence*
DNA / genetics*
Patents as Topic*
United States

Substances

Biological Products
DNA